Marshall Wace Asia’s Pfizer PFE Stock Holding History

Marshall Wace Asia’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-60,570	Closed	-$2.19M	–	159
2021 Q1	$2.19M	Buy	+60,570	New	+$2.15M	0.05%	105
2020 Q2	–	Sell	-46,821	Closed	-$1.45M	–	153
2020 Q1	$1.45M	Buy	+46,821	New	+$1.6M	0.04%	69
2019 Q2	–	Sell	-53,641	Closed	-$2.16M	–	130
2019 Q1	$2.16M	Buy	+53,641	New	+$2.15M	0.07%	75

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Marshall Wace Asia's PFE Position: Q2 2021 in Review

Marshall Wace Asia sold out of Pfizer (PFE) in Q2 2021, closing a stake of 60,570 shares — an estimated $2.19M sold.

Marshall Wace Asia first reported a position in PFE in Q1 2019 and held it in 3 quarters. The position peaked at $2.19M in Q1 2021. 2,733 funds tracked by Wall St. Rank hold PFE as of Q2 2021.

Marshall Wace Asia reported no remaining Pfizer position as of Q2 2021 after selling out during the quarter.
Marshall Wace Asia sold 60,570 Pfizer shares in Q2 2021, an estimated $2.19M.
Marshall Wace Asia first reported a position in Pfizer in Q1 2019 and held it in 3 quarters.
Marshall Wace Asia's Pfizer position peaked at $2.19M in Q1 2021.
2,733 funds tracked by Wall St. Rank held Pfizer as of Q2 2021.

Based on Marshall Wace Asia's 13F filing for Q2 2021, filed 13 Aug 2021.